Evidence map›Paper›PMID 41017961›Full record

ArticleHemaSphere2025

Xq24/

Lukas Marcelis, Ryan Nicolaas Allsop, Marlies Vanden Bempt, Koen Debackere, Félicien Renard, Stefania Tuveri, Daan Dierickx, Adrian Janiszewski, Bradley Philip Balaton, Johanna Vets and 8 more

Abstract read
In one paragraph

Article in HemaSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Lukas MarcelisTranslational Cell and Tissue Research KU Leuven Leuven Belgium.
Ryan Nicolaas AllsopDepartment of Development and Regeneration Leuven Stem Cell Institute Leuven Belgium.
Marlies Vanden BemptDepartment of Oncology KU Leuven Leuven Belgium.
Koen DebackereDepartment of Oncology KU Leuven Leuven Belgium.
Félicien RenardDepartment of Oncology KU Leuven Leuven Belgium.
Stefania TuveriCentre for Human Genetics KU Leuven Leuven Belgium.ORCID https://orcid.org/0000-0003-4051-4295
Daan DierickxDepartment of Hematology University Hospitals Leuven Leuven Belgium.ORCID https://orcid.org/0000-0002-8917-022X
Adrian JaniszewskiDepartment of Development and Regeneration Leuven Stem Cell Institute Leuven Belgium.
Bradley Philip BalatonDepartment of Development and Regeneration Leuven Stem Cell Institute Leuven Belgium.
Johanna VetsTranslational Cell and Tissue Research KU Leuven Leuven Belgium.
Barbara DewaeleCentre for Human Genetics KU Leuven Leuven Belgium.
Lucienne MichauxCentre for Human Genetics KU Leuven Leuven Belgium.
Peter VandenbergheCentre for Human Genetics KU Leuven Leuven Belgium.
Jan CoolsVIB-KU Center for Cancer Biology Leuven Belgium.ORCID https://orcid.org/0000-0001-6626-5843
Joris Robert VermeeschCentre for Human Genetics KU Leuven Leuven Belgium.
Thomas TousseynTranslational Cell and Tissue Research KU Leuven Leuven Belgium.
Vincent PasqueDepartment of Development and Regeneration Leuven Stem Cell Institute Leuven Belgium.
Iwona WlodarskaCentre for Human Genetics KU Leuven Leuven Belgium.ORCID https://orcid.org/0000-0001-7455-4135

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Female-biased incidence in primary mediastinal large B-cell lymphoma (PMBCL) is enigmatic and points to a potential contribution of the X chromosome in this disease. To elucidate the postulated involvement of X-linked factor(s), we profiled the X chromosome in 48 diagnostic PMBCLs of male (21) and female (27) origin. Molecular cytogenetic analysis detected copy number gain of X/Xq in all male patients and 59.3% (16/27) of female patients. The remaining female cases revealed either a cytogenetically cryptic copy-neutral loss of heterozygosity (CNLOH) of X/Xq (14.8%) or germline XX (25.9%). Remarkably, RNAseq data of 28 cases indicated a nonrandom involvement of transcriptionally active X homolog in gain/CNLOH, validated by

Identifiers

PMID41017961
PMCPMC12475935

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.